BLA 761197 · Genentech INC
Susvimo
Ranibizumab · Injection · Vascular Endothelial Growth Factor Inhibitor
Priority reviewLast checked: Nov 20, 2026Latest source record: Sep 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Oct 22, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
538
153 Phase 3, 12 recruiting
FAERS reports
5,319
5,059 serious, 751 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. [see Contraindications (4.1) , Warnings and Precautions (5.1) ] . WARNING: ENDOPHTHALMITIS See full prescribing information for complete boxed warning. The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.
What it is approved for
From the label in effect Nov 21, 2025.
SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ). 1.1 Neovascular (wet) Age-related Macular Degeneration (AMD) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. 1.2 Diabetic Macular Edema (DME) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. 1.3 Diabetic Retinopathy (DR) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.
Mechanism: Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 21, 2025 Supplement 7 · Efficacy LetterLabel
- Feb 3, 2025 Supplement 6 · Efficacy LabelLetter
- Oct 22, 2021 Original approval · Type 2 - New Active Ingredient · priority review LetterLabelReview
1 products under this application
- SUSVIMO · RANIBIZUMAB 100MG/ML · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ranibizumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00251459 · 5,000 participants · Start Nov 2005
Drug: rhuFab V2 (ranibizumab) · For: Choroidal Neovascularization; Age-related Macular Degeneration
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00637377 · 1,240 participants · Start Apr 2008 · Primary completion Sep 2010
Drug: Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Rosario, Argentina · 189 sites in all
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00509795 · 1,217 participants · Start Aug 2007 · Primary completion Sep 2010
Drug: ranibizumab; aflibercept injection (VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 188 sites in all
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin TrialPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT00593450 · 1,208 participants · Start Feb 2008 · Primary completion Dec 2010
Drug: ranibizumab; bevacizumab · For: Age Related Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 59 sites in all
- A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00891735 · 1,097 participants · Start Jul 2009 · Primary completion Aug 2011
Drug: Ranibizumab · For: Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Arcadia, California · 99 sites in all
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01986907 · 1,049 participants · Start Mar 4, 2014 · Primary completion Jun 15, 2016
Drug: ranibizumab · For: Wet Age Related Macular Degeneration
Sites: Alessandria, Italy; Casale Monferrato, Italy; Ancona, Italy · 101 sites in all
Kagawa UniversityAcademic, hospital or other
NCT02321267 · 1,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Hiragi, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual acuity reduced545
- death380
- off label use295
- retinal haemorrhage270
- cerebrovascular accident265
- vitreous haemorrhage214
- drug ineffective209
- endophthalmitis207
- myocardial infarction181
- visual impairment172
- cataract164
- retinal pigment epithelial tear149
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 3 |
| 2007 | 53 |
| 2008 | 67 |
| 2009 | 142 |
| 2010 | 241 |
| 2011 | 240 |
| 2012 | 565 |
| 2013 | 996 |
| 2014 | 442 |
| 2015 | 334 |
| 2016 | 234 |
| 2017 | 193 |
| 2018 | 208 |
| 2019 | 208 |
| 2020 | 129 |
| 2021 | 162 |
| 2022 | 253 |
| 2023 | 277 |
| 2024 | 210 |
| 2025 | 219 |
| 2026 | 143 |
Recalls
1 FDA enforcement reports for this application.
Oct 18, 2022 · Class III · Terminated
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Susvimo* (Ranibizumab*) · HCPCS J2779
2024 spending
$2.2M
Beneficiaries
195
294 claims
Per beneficiary
$11,516
2024 ASP limit $80.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $825,096 |
| 2023 | $1,669,238 |
| 2024 | $2,245,604 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
Stahl A, Lepore D, Fielder A, et al. · Lancet 2019 · Multicenter Study, Randomized Controlled Trial
- Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.
Khanani AM, Campochiaro PA, Graff JM, et al. · JAMA Ophthalmol 2025 · Clinical Trial, Phase III, Equivalence Trial
- Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, et al. · N Engl J Med 2006 · Clinical Trial, Phase III, Multicenter Study
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, et al. · Ophthalmology 2012 · Clinical Trial, Phase III, Comparative Study
- Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Takeda AL, Colquitt J, Clegg AJ, et al. · Br J Ophthalmol 2007 · Research Support, Non-U.S. Gov't, Systematic Review
- Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Wells JA, Glassman AR, Ayala AR, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.